Cargando…

In Silico Evaluation of Paxlovid’s Pharmacometrics for SARS-CoV-2: A Multiscale Approach

Paxlovid is a promising, orally bioavailable novel drug for SARS-CoV-2 with excellent safety profiles. Our main goal here is to explore the pharmacometric features of this new antiviral. To provide a detailed assessment of Paxlovid, we propose a hybrid multiscale mathematical approach. We demonstrat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartha, Ferenc A., Juhász, Nóra, Marzban, Sadegh, Han, Renji, Röst, Gergely
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9146265/ https://www.ncbi.nlm.nih.gov/pubmed/35632843 http://dx.doi.org/10.3390/v14051103

Ejemplares similares

A hybrid PDE–ABM model for viral dynamics with application to SARS-CoV-2 and influenza
por: Marzban, Sadegh, et al.
Publicado: (2021)

An explanation for SARS-CoV-2 rebound after Paxlovid treatment
por: Perelson, Alan S., et al.
Publicado: (2023)

Paxlovid: Mechanism of Action, Synthesis, and In Silico Study
por: Marzi, Mahrokh, et al.
Publicado: (2022)

Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection
por: Sun, Fangfang, et al.
Publicado: (2022)

Mathematical model of SARS-CoV-2 immunity predicts Paxlovid rebound
por: Ranard, Benjamin L., et al.
Publicado: (2023)

Special Considerations for Paxlovid Treatment Among Transplant Recipients With SARS-CoV-2 Infection
por: Fishbane, Steven, et al.
Publicado: (2022)

The Path to Paxlovid
por: Halford, Bethany
Publicado: (2022)

Editorial: Rebound COVID-19 and Cessation of Antiviral Treatment for SARS-CoV-2 with Paxlovid and Molnupiravir
por: Parums, Dinah V.
Publicado: (2022)

Interactions of the Anti-SARS-CoV-2 Agents Molnupiravir and Nirmatrelvir/Paxlovid with Human Drug Transporters
por: Bakos, Éva, et al.
Publicado: (2023)

Characterizing SARS-CoV-2 Viral Clearance Kinetics to Improve the Design of Antiviral Pharmacometric Studies
por: Watson, James A., et al.
Publicado: (2022)

A sustainable synthesis of the SARS-CoV-2 M(pro) inhibitor nirmatrelvir, the active ingredient in Paxlovid
por: Kincaid, Joseph R. A., et al.
Publicado: (2022)

Paxlovid: A promising drug for the challenging treatment of SARS-COV-2 in the pandemic era
por: Niraj, Niraj, et al.
Publicado: (2022)

Metaheuristics for pharmacometrics
por: Kim, Seongho, et al.
Publicado: (2021)

The neutralization effect of montelukast on SARS-CoV-2 is shown by multiscale in silico simulations and combined in vitro studies
por: Durdagi, Serdar, et al.
Publicado: (2022)

A 1-Pot Synthesis of the SARS-CoV-2 M(pro) Inhibitor Nirmatrelvir, the Key Ingredient in Paxlovid
por: Caravez, Juan C., et al.
Publicado: (2022)

Clinical efficacy analysis of paxlovid in children with hematological diseases infected with the omicron SARS-CoV-2 new variant
por: Li, Yixian, et al.
Publicado: (2023)

Pharmacometrics Approaches and its Applications in Diabetes: An Overview
por: Aziz, Sohail, et al.
Publicado: (2021)

The future of Paxlovid for COVID-19
por: Burki, Talha
Publicado: (2022)

Ranolazine Toxicity Secondary to Paxlovid
por: Casey, Bradley, et al.
Publicado: (2023)

Pharmacometrics: Focus on the Patient
por: Dumitrescu, T Pene, et al.
Publicado: (2015)

Commentary on Pharmacometrics for Immunotherapy
por: Garrido, MJ, et al.
Publicado: (2017)

Pharmacometrics and/or Systems Pharmacology
por: van der Graaf, Piet H.
Publicado: (2019)

Paxlovid with Caution: Novel Case of Paxlovid-Induced Tacrolimus Toxicity in a Cardiac Transplant Patient
por: Shah, Aaisha, et al.
Publicado: (2022)

The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics
por: van Hasselt, J G Coen, et al.
Publicado: (2012)

Response to “Pharmacometric Approach to Evaluate Drug Dosing Adherence”
por: Ding, Junjie, et al.
Publicado: (2020)

Circulating tumor DNA: Opportunities and challenges for pharmacometric approaches
por: Ribba, Benjamin, et al.
Publicado: (2023)

COVID 19, Paxlovid and the lesson from rare genetic diseases with naturally occurring protection from SARS-CoV-2 infection
por: Calò, Lorenzo A., et al.
Publicado: (2022)

The efficacy of paxlovid in elderly patients infected with SARS-CoV-2 omicron variants: Results of a non-randomized clinical trial
por: Zhong, Weijie, et al.
Publicado: (2022)

The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2
por: Park, Hanul, et al.
Publicado: (2022)

Paxlovid™ jetzt direkt an Patienten abgeben
por: Zimmermann, Gerd W.
Publicado: (2022)

Paxlovid-Induced Symptomatic Bradycardia and Syncope
por: Ganipisetti, Venu M, et al.
Publicado: (2023)

CARDIOGENIC SHOCK DUE TO PAXLOVID INTERACTION
por: Enstrom, Cate, et al.
Publicado: (2023)

Serotonin Syndrome Precipitated by Paxlovid Initiation
por: Nasser, Nicholas G, et al.
Publicado: (2023)

CPT: Pharmacometrics and Systems Pharmacology
por: van der Graaf, Piet H
Publicado: (2012)

Opinion: The Pharmacometrics of Infectious Disease
por: Davies, G R, et al.
Publicado: (2013)

Pharmacometric Characterization of Dabigatran Hemodialysis
por: Liesenfeld, Karl-Heinz, et al.
Publicado: (2013)

CPT: Pharmacometrics & Systems Pharmacology
Publicado: (2013)

CORRIGENDUM: Commentary on Pharmacometrics for Immunotherapy
por: Garrido, MJ, et al.
Publicado: (2017)

Nirmatrelvir más ritonavir (Paxlovid) una potente combinación inhibidora de la proteasa 3CLpro del SARS-CoV-2
por: Reina, Jordi, et al.
Publicado: (2022)

Genetic Surveillance of SARS-CoV-2 M(pro) Reveals High Sequence and Structural Conservation Prior to the Introduction of Protease Inhibitor Paxlovid
por: Lee, Jonathan T., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_78ub3mnk6f5oeg0lrtri39sh0u